**Web Summary**

**Title: ISLEND-2**

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care

**Objective:**

The objective of this study is to evaluate the efficacy of switching to an investigational weekly oral tablet containing the two medications islatravir and lenacapavir versus continuing current standard of care treatment in virologically suppressed People with HIV.

**Eligibility:**

You may be eligible to take part in this study if you:

* have HIV-1 infection
* are at least 18 years old
* have been on a standard combination of medications to treat HIV for at least 6 months
* have an undetectable HIV viral load (HIV-1 RNA levels < 50 copies/mL)

The study team will discuss other criteria with you.

**Description:**

People in this study will be randomly placed into 1 of 2 groups:

* Group 1 will receive the investigational combination tablet of islatravir and lenacapavir once per week for at least 96 weeks
* Group 2 will continue their current standard of care treatment for 96 weeks and then be given the option to switch to the weekly pill.

**Study Sponsor: Gilead Sciences**

**For further information, please visit:**

[**https://clinicaltrials.gov/study/NCT05052996**](https://clinicaltrials.gov/study/NCT05052996)

***Or***

**Contact CRI’s Research Team at**

**617.502.1707 or info@crihealth.org**